Insys-Therapeutics (INSY) Announces Buprenorphine Sublingual-Spray Phase-3 Met Primary-Endpoint http://www.streetinsider.com/Corporate+News/Insys+Therapeutics+(INSY)+Announces+Buprenorphine+Sublingual+Spray+Phase+3+Met+Primary+Endpoint/11967228.html https://clinicaltrials.gov/ct2/show/NCT02634788?term=NCT02634788&rank=1